Karyopharm rises on Bristol Myers collaboration for blood cancer therapy
30/10/2023 12:56
** Shares of Karyopharm Therapeutics KPTI.O rise ~5.5% to
87 cents premarket
** Drugmaker says it is collaborating with Bristol Myers
Squibb BMY.N to evaluate a combination of KPTI's therapy
Xpovio and BMY's CELMoD for multiple myeloma patients
** Clinical trials expected to start in first half of 2024
** Up to last close, shares down 75.8% YTD
(Reporting by Christy Santhosh)
((Christy.Santhosh@thomsonreuters.com))